Literature DB >> 24623592

Treatment options for covert hepatic encephalopathy.

Nisheet Waghray1, Abhijeet Waghray, Kevin Mullen.   

Abstract

OPINION STATEMENT: The main issue with treating covert hepatic encephalopathy (HE) is to establish whether it is cost effective to reverse the neuropsychiatric abnormalities that define this mild form of HE. Until fairly recently, covert HE was rarely diagnosed, but advances in computerized psychometric testing have greatly simplified its detection. The many consequences of covert HE are now being identified, and most have been shown to be reversible with standard HE treatment. Perhaps the most enticing possibility will be the potential that standard HE therapies will postpone the onset of overt HE. This will require further evaluation with large placebo-controlled randomized trials.

Entities:  

Year:  2014        PMID: 24623592     DOI: 10.1007/s11938-014-0014-y

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  75 in total

1.  Critical flicker frequency for quantification of low-grade hepatic encephalopathy.

Authors:  Gerald Kircheis; Matthias Wettstein; Lars Timmermann; Alfons Schnitzler; Dieter Häussinger
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

2.  Can we ignore minimal hepatic encephalopathy any longer?

Authors:  Asif M Qadri; Ben O Ogunwale; Kevin D Mullen
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

Review 3.  Management options for minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

4.  Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study.

Authors:  Piero Amodio; Francesca Campagna; Stefania Olianas; Pamela Iannizzi; Daniela Mapelli; Marco Penzo; Paolo Angeli; Angelo Gatta
Journal:  J Hepatol       Date:  2008-06-02       Impact factor: 25.083

5.  Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy.

Authors:  Dina H Ziada; Hanan H Soliman; Saher A El Yamany; Manal F Hamisa; Azza M Hasan
Journal:  Arab J Gastroenterol       Date:  2013-09-23       Impact factor: 2.076

6.  Use of ImPACT to diagnose minimal hepatic encephalopathy: an accurate, practical, user-friendly internet-based neuropsychological test battery.

Authors:  Matthew Tsushima; William Tsushima; Vincent Tsushima; Nelson Lim; Erika Madrigal; Christian Jackson; Michel Henry Mendler
Journal:  Dig Dis Sci       Date:  2013-04-27       Impact factor: 3.199

7.  Characterization of fecal microbial communities in patients with liver cirrhosis.

Authors:  Yanfei Chen; Fengling Yang; Haifeng Lu; Baohong Wang; Yunbo Chen; Dajiang Lei; Yuezhu Wang; Baoli Zhu; Lanjuan Li
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

8.  Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients.

Authors:  J S Bajaj; A J Sanyal; D Bell; H Gilles; D M Heuman
Journal:  Aliment Pharmacol Ther       Date:  2010-02-05       Impact factor: 8.171

9.  Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.

Authors:  P Brigidi; E Swennen; F Rizzello; M Bozzolasco; D Matteuzzi
Journal:  J Chemother       Date:  2002-06       Impact factor: 1.714

10.  Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.